Eunice Wang, MD, on Treating AML During the COVID-19 Pandemic
The leukemia expert spoke about the importance of genetic testing for patients with acute myeloid leukemia and other important considerations for this patient population throughout the pandemic.
For patients with acute myeloid leukemia (AML), an aggressive form of blood cancer that presents with a variety of subtypes, the coronavirus disease 2019 (COVID-19) pandemic has posed new challenges.
With the advent of these new challenges, researchers recommend that patients with AML undergo genetic testing for mutations to provide important information on the treatment options available.
In an interview with CancerNetwork®, Eunice Wang, MD, chief of Leukemia at the Roswell park Comprehensive Cancer Center, explained why genetic testing is so critical for this patient population and discussed other important considerations for patients with AML throughout the pandemic.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
